Clinical trials: cTACE
Hypervascular Tumors
Instylla HES Hypervascular Tumor Pivotal Study
To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional…
- Trial name
- NCT04523350
- Testing
- Instylla HES, TAE or cTACE
- Where
- 15 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Instylla, Inc.